Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotte...
23 Janeiro 2019 - 11:31AM
Zug, Switzerland, January 23, 2019 - Auris
Medical Holding AG (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology and central nervous system disorders,
today highlighted the advance publication of an article
demonstrating that betahistine promotes the retrieval of forgotten
memories in mice and in healthy human volunteers. The peer-reviewed
article titled "Central histamine boosts perirhinal cortex activity
and restores forgotten object memories" is currently in print in
Biological Psychiatry, one of the most highly cited journals in the
field of psychiatric neuroscience.[1]
The article was written by an independent
Japanese research group and presents the outcomes of a study on the
role of histamine in the recollection of forgotten memories and the
effects of using histamine H3 receptor inverse agonists for
treatment. In the first part of the study, the authors demonstrated
in mice that treatment with betahistine or thioperamide induced the
recall of forgotten memories of certain objects one week or one
month later. They showed that the memory recovery was promoted by
the H3 receptor inverse agonists through upregulation of histamine
release in the brain, the following activation of histamine H2
receptors and increased spontaneous activity in perirhinal cortex
neurons.
In the second part of the study, 38 healthy
adult volunteers were enrolled in a randomized double-blind,
placebo-controlled crossover trial. At baseline, they were shown
128 pictures of objects. Seven days after the training, they were
shown again 32 of these objects, randomly mixed with 32 new objects
and 32 objects that were similar, but not identical to previously
shown images, and asked to decide whether each image was "old",
"new" or "similar". Thirty minutes prior to the test, they received
in a single dose either 108 mg betahistine mesilate, (i.e. three
times the approved daily oral dose) or placebo. The test was
repeated two days later, with different images, and with
active-treated participants switching over to placebo and vice
versa. Treatment with betahistine overall improved the percentage
of correct memories (p<0.05), enhanced the retrieval of more
difficult items and benefited participants with poor performance
under placebo treatment (p<0.01).
"The exciting outcomes from this study add to
the growing body of evidence supporting the important role of
histamine in the acquisition, storage and retrieval of memory and
suggest further potential uses for betahistine," commented Thomas
Meyer, Auris Medical's founder, Chairman and CEO. "Histamine plays
a key role in the regulation of a wide range of behavioral and
physiological functions, including appetite, drinking, sleep,
wakefulness, learning, attention and memory. Earlier studies with
betahistine already showed positive effects on learning and
cognitive function. While betahistine's clinical utility has been
limited by poor bioavailability when administered orally, our
intranasal formulation allows for significantly higher plasma
exposure, which is expected to translate into better therapeutic
outcomes and open up new therapeutic uses."
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in neurotology and mental health supportive
care. The company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125) and for the
prevention of antipsychotic-induced weight gain and somnolence
(AM-201). These projects have gone through two Phase 1 trials and
will move into proof-of-concept studies in 2019. In addition Auris
Medical has two Phase 3 programs under development: Sonsuvi®
(AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101)
for acute inner ear tinnitus. The Company was founded in 2003 and
is headquartered in Zug, Switzerland. The shares of Auris Medical
Holding AG trade on the NASDAQ Capital Market under the symbol
"EARS."
Forward-looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical facts and may include statements
that address future operating, financial or business performance or
Auris Medical's strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may",
"might", "will", "should", "expects", "plans", "anticipates",
"believes", "estimates", "predicts", "projects", "potential",
"outlook" or "continue", or the negative of these terms or other
comparable terminology. Forward-looking statements are based on
management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, Auris Medical's need
for and ability to raise substantial additional funding to continue
the development of its product candidates, the ability to pursue
strategic partnering and non-dilutive funding for its Phase 3
programs, the results of Auris Medical's review of strategic
options and the outcome of any action taken as a result of such
review, the timing and conduct of clinical trials of Auris
Medical's product candidates, the clinical utility of Auris
Medical's product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical's intellectual
property position and Auris Medical's financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Auris Medical's Annual Report
on Form 20-F for the year ended December 31, 2017, and in Auris
Medical's other filings with the SEC, which are available free of
charge on the Securities Exchange Commission's website at:
www.sec.gov. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those indicated. All
forward-looking statements and all subsequent written and oral
forward-looking statements attributable to Auris Medical or to
persons acting on behalf of Auris Medical are expressly qualified
in their entirety by reference to these risks and uncertainties.
You should not place undue reliance on forward-looking statements.
Forward-looking statements speak only as of the date they are made,
and Auris Medical does not undertake any obligation to update them
in light of new information, future developments or otherwise,
except as may be required under applicable law.
Investor contact: Joseph Green / Andrew Gibson Edison
Advisors for Auris Medical 646-653-7030 / 7719
jgreen@edisongroup.com / agibson@edisongroup.com
Or
investors@aurismedical.com
[1] Nomura H et al. Central histamine boosts perirhinal cortex
activity and restores forgotten object memories. Biol Psychiatry.
In press.
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024